Evidence map›Paper›PMID 26427657›Full record

ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2016

ROBO1 deletion as a novel germline alteration in breast and colorectal cancer patients.

Rolando A R Villacis, Francine B Abreu, Priscila M Miranda, Maria A C Domingues, Dirce M Carraro, Erika M M Santos, Victor P Andrade, Benedito M Rossi, Maria I Achatz, Silvia R Rogatto

Abstract read
PubMed Publisher
In one paragraph

Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Rolando A R VillacisInternational Research Center (CIPE), A.C. Camargo Cancer Center, Rua Taguá 440, São Paulo, CEP: 01508-010, SP, Brazil.
Francine B AbreuInternational Research Center (CIPE), A.C. Camargo Cancer Center, Rua Taguá 440, São Paulo, CEP: 01508-010, SP, Brazil.
Priscila M MirandaInternational Research Center (CIPE), A.C. Camargo Cancer Center, Rua Taguá 440, São Paulo, CEP: 01508-010, SP, Brazil.
Maria A C DominguesDepartment of Pathology, Faculty of Medicine, University of São Paulo State (UNESP), Botucatu, SP, Brazil.
Dirce M CarraroInternational Research Center (CIPE), A.C. Camargo Cancer Center, Rua Taguá 440, São Paulo, CEP: 01508-010, SP, Brazil.
Erika M M SantosOncology Center, Sírio-Libanês Hospital, São Paulo, SP, Brazil.
Victor P AndradeDepartment of Pathology, A.C. Camargo Cancer Center, São Paulo, SP, Brazil.
Benedito M RossiOncology Center, Sírio-Libanês Hospital, São Paulo, SP, Brazil.
Maria I AchatzDepartment of Oncogenetics, A.C. Camargo Cancer Center, São Paulo, SP, Brazil.
Silvia R RogattoInternational Research Center (CIPE), A.C. Camargo Cancer Center, Rua Taguá 440, São Paulo, CEP: 01508-010, SP, Brazil. rogatto@fmb.unesp.br.
AC Camargo Hospital · BRHospital Sírio-Libanês · BRUniversidade Estadual Paulista (Unesp) · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite one third of breast (BC) and colorectal cancer (CRC) cases having a hereditary component, only a small proportion can be explained by germline mutations. The aim of this study was to identify potential genomic alterations related to cancer predisposition. Copy number variations (CNVs) were interrogated in 113 unrelated cases fulfilling the criteria for hereditary BC/CRC and presenting non-pathogenic mutations in BRCA1, BRCA2, MLH1, MSH2, TP53, and CHEK2 genes. An identical germline deep intronic deletion of ROBO1 was identified in three index patients using two microarray platforms (Agilent 4x180K and Affymetrix CytoScan HD). The ROBO1 deletion was confirmed by quantitative PCR (qPCR). Six relatives were also evaluated by CytoScan HD Array. Genomic analysis confirmed a co-segregation of the ROBO1 deletion with the occurrence of cancer in two families. Direct sequencing revealed no pathogenic ROBO1 point mutations. Transcriptomic analysis (HTA 2.0, Affymetrix) in two breast carcinomas from a single patient revealed ROBO1 down-expression with no splicing events near the intronic deletion. Deeper in silico analysis showed several enhancer regions and a histone methylation mark in the deleted region. The ROBO1 deletion in a putative transcriptional regulatory region, its down-expression in tumor samples, and the results of the co-segregation analysis revealing the presence of the alteration in affected individuals suggest a pathogenic effect of the ROBO1 in cancer predisposition.

Indexed as

Gene DeletionAdultAgedBreast NeoplasmsColorectal NeoplasmsDNA Copy Number VariationsFemaleGene Expression ProfilingHumansMaleMiddle AgedNerve Tissue ProteinsReceptors, ImmunologicRoundabout ProteinsNerve Tissue ProteinsReceptors, ImmunologicRoundabout ProteinsBreast carcinomaColorectal cancerGermline deletionHereditary cancerROBO1

Identifiers

PMID26427657
OpenAlexW1823244778

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.